AAVantgarde Receives FDA Clearance to Progress Stargardt Disease Asset, AAVB-039, into CELESTE, a Phase 1/2 Clinical Trial
AAVB-039 delivers the full-length ABCA4 -protein, addressing the root cause of the disease and enabling treatment of all patients, independent of mutation CELESTE is informed by the STELLA prospective natural history study, which is currently enrolling patients in the United States and Europe AAVB-039 uses AAVantgarde’s proprietary dual AAV intein platform. The platform has achieved [...]










